

Kenneth E Lipson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1843615/publications.pdf>

Version: 2024-02-01

79
papers

4,630
citations

87843

38
h-index

98753

67
g-index

80
all docs

80
docs citations

80
times ranked

6667
citing authors

#	ARTICLE	IF	CITATIONS
1	CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. <i>Fibrogenesis and Tissue Repair</i> , 2012, 5, S24.	3.4	453
2	Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. <i>Journal of Experimental Medicine</i> , 2005, 201, 925-935.	4.2	345
3	Inhibition of $\alpha_3\beta_1$ Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 6270-6279.	3.2	210
4	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 272-285.	2.9	182
5	Trimodal Cancer Treatment: Beneficial Effects of Combined Antiangiogenesis, Radiation, and Chemotherapy. <i>Cancer Research</i> , 2005, 65, 3643-3655.	0.4	171
6	The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. <i>Oncogene</i> , 2004, 23, 5387-5393.	2.6	170
7	Combination of Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor Inhibition Markedly Improves Radiation Tumor Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 2210-2219.	3.2	125
8	Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. <i>Cancer Research</i> , 2003, 63, 8890-8.	0.4	125
9	SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. <i>Cancer Research</i> , 2003, 63, 3755-63.	0.4	124
10	Blockade of Vascular Endothelial Growth Factor Receptor I (VEGF-RI), but not VEGF-RII, Suppresses Joint Destruction in the K/BxN Model of Rheumatoid Arthritis. <i>Journal of Immunology</i> , 2003, 171, 4853-4859.	0.4	121
11	Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy. <i>Human Molecular Genetics</i> , 2013, 22, 4938-4951.	1.4	118
12	Identification of Substituted 3-[(4,5,6,7-Tetrahydro-1H-indol-2-yl)methylene]- 1,3-dihydroindol-2-ones as Growth Factor Receptor Inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-RI ² Tyrosine Kinases. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 2655-2663.	2.9	112
13	Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	106
14	The STE20 Kinase HGK Is Broadly Expressed in Human Tumor Cells and Can Modulate Cellular Transformation, Invasion, and Adhesion. <i>Molecular and Cellular Biology</i> , 2003, 23, 2068-2082.	1.1	103
15	Comparison of human B cell activation by TLR7 and TLR9 agonists. <i>BMC Immunology</i> , 2008, 9, 39.	0.9	103
16	TLR \times TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF- α . <i>International Immunopharmacology</i> , 2007, 7, 1111-1121.	1.7	90
17	ERK1/2 directly acts on CTGF/CCN2 expression to mediate myocardial fibrosis in cardiomyopathy caused by mutations in the lamin A/C gene. <i>Human Molecular Genetics</i> , 2016, 25, 2220-2233.	1.4	76
18	Connective Tissue Growth Factor Inhibition Attenuates Left Ventricular Remodeling and Dysfunction in Pressure Overload-Induced Heart Failure. <i>Hypertension</i> , 2014, 63, 1235-1240.	1.3	75

#	ARTICLE	IF	CITATIONS
19	Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC. <i>Radiation Oncology</i> , 2018, 13, 1.	1.2	73
20	Receptor tyrosine kinases as targets for inhibition of angiogenesis. <i>Drug Discovery Today</i> , 1997, 2, 50-63.	3.2	72
21	Resiquimod and other immune response modifiers as vaccine adjuvants. <i>Expert Review of Vaccines</i> , 2007, 6, 835-847.	2.0	72
22	Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists. <i>BMC Immunology</i> , 2007, 8, 26.	0.9	66
23	Measurement of the Protein Tyrosine Kinase Activity of c-src Using Time-Resolved Fluorometry of Europium Chelates. <i>Analytical Biochemistry</i> , 1996, 238, 159-164.	1.1	64
24	Connective Tissue Growth Factor Antibody Therapy Attenuates Hyperoxia-Induced Lung Injury in Neonatal Rats. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 1169-1177.	1.4	63
25	Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis. <i>Scientific Reports</i> , 2017, 7, 5392.	1.6	63
26	Anti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2017, 19, 134.	1.6	63
27	Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors. <i>Oncotarget</i> , 2015, 6, 4663-4676.	0.8	62
28	A Solid-Phase Assay for the Determination of Protein Tyrosine Kinase Activity of c-src Using Scintillating Microtitration Plates. <i>Analytical Biochemistry</i> , 1996, 234, 23-26.	1.1	61
29	Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1220-1232.	0.4	58
30	Anti-Connective Tissue Growth Factor Antibody Treatment Reduces Extracellular Matrix Production in Trabecular Meshwork and Lamina Cribrosa Cells. , 2013, 54, 7836.		56
31	Weekly Dosing With the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor SU9518 Significantly Inhibits Arterial Stenosis. <i>Circulation Research</i> , 2001, 88, 630-636.	2.0	54
32	Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. <i>Radiation Oncology</i> , 2009, 4, 66.	1.2	53
33	Denervation-induced skeletal muscle fibrosis is mediated by CTGF/CCN2 independently of TGF- β ² . <i>Matrix Biology</i> , 2019, 82, 20-37.	1.5	52
34	Connective Tissue Growth Factor Inhibition Enhances Cardiac Repair and Limits Fibrosis After Myocardial Infarction. <i>JACC Basic To Translational Science</i> , 2019, 4, 83-94.	1.9	48
35	Human Glioblastoma and Carcinoma Xenograft Tumors Treated by Combined Radiation and Imatinib (Gleevec®). <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 400-407.	1.0	45
36	Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells. <i>BMC Cancer</i> , 2006, 6, 79.	1.1	45

#	ARTICLE	IF	CITATIONS
37	Role of hypoxia in skeletal muscle fibrosis: Synergism between hypoxia and TGF- β signaling upregulates CCN2/CTGF expression specifically in muscle fibers. <i>Matrix Biology</i> , 2020, 87, 48-65.	1.5	45
38	Connective-Tissue Growth Factor Contributes to TGF- β -induced Lung Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 66, 260-270.	1.4	45
39	Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer. <i>Radiotherapy and Oncology</i> , 2015, 114, 173-181.	0.3	43
40	Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C- and VEGF-A-induced angiogenesis in vitro. <i>Experimental Cell Research</i> , 2003, 285, 286-298.	1.2	39
41	The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. <i>Lung Cancer</i> , 2004, 46, 283-291.	0.9	38
42	Adventitial Microvessel Formation After Coronary Stenting and the Effects of SU11218, a Tyrosine Kinase Inhibitor. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1067-1075.	1.2	37
43	Unusual DNA binding characteristics of an in vitro translation product of the CCAAT binding protein mYB-1. <i>Nucleic Acids Research</i> , 1992, 20, 601-606.	6.5	35
44	Two zinc-dependent steps during G1 to S phase transition. <i>Journal of Cellular Physiology</i> , 1993, 155, 445-451.	2.0	34
45	Structure and proteolysis of the growth hormone receptor on rat hepatocytes. <i>Biochemistry</i> , 1987, 26, 4438-4443.	1.2	32
46	TLR7 Agonist 852A Inhibition of Tumor Cell Proliferation Is Dependent on Plasmacytoid Dendritic Cells and Type I IFN. <i>Journal of Interferon and Cytokine Research</i> , 2008, 28, 253-263.	0.5	32
47	The inhibition of CTGF/CCN2 activity improves muscle and locomotor function in a murine ALS model. <i>Human Molecular Genetics</i> , 2018, 27, 2913-2926.	1.4	29
48	NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 575-587.	2.0	27
49	FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition. <i>Pharmaceutical Research</i> , 2016, 33, 1833-1849.	1.7	26
50	Vascular Endothelial Cell-Specific Connective Tissue Growth Factor (CTGF) Is Necessary for Development of Chronic Hypoxia-Induced Pulmonary Hypertension. <i>Frontiers in Physiology</i> , 2018, 9, 138.	1.3	26
51	Connective tissue growth factor regulates cardiac function and tissue remodeling in a mouse model of dilated cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 89, 214-222.	0.9	25
52	CGS 27830, a potent nonpeptide endothelin receptor antagonist. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1993, 3, 2099-2104.	1.0	19
53	Carboxy-Substituted Cinnamides: A Novel Series of Potent, Orally Active LTB4 Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 164-172.	2.9	19
54	Plasma Connective Tissue Growth Factor (CTGF/CCN2) Levels Predict Myocardial Infarction in the Veterans Affairs Diabetes Trial (VADT) Cohort. <i>Diabetes Care</i> , 2018, 41, 840-846.	4.3	18

#	ARTICLE	IF	CITATIONS
55	Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab. <i>Respiratory Research</i> , 2018, 19, 14.	1.4	18
56	Driving fibrosis in neuromuscular diseases: Role and regulation of Connective tissue growth factor (CCN2/CTGF). <i>Matrix Biology Plus</i> , 2021, 11, 100059.	1.9	18
57	Potential of the antitumor effects of imidazoquinoline immune response modifiers by cyclophosphamide. <i>Cancer Biology and Therapy</i> , 2010, 10, 155-165.	1.5	17
58	Effect of growth hormone on protein phosphorylation in isolated rat hepatocytes. <i>Biochemistry</i> , 1987, 26, 715-721.	1.2	14
59	Characterization of glucagon receptors in Golgi fractions of rat liver: evidence for receptors that are uncoupled from adenylyl cyclase. <i>Biochemistry</i> , 1986, 25, 2612-2620.	1.2	13
60	N-Ethylmaleimide uncouples the glucagon receptor from the regulatory component of adenylyl cyclase. <i>Biochemistry</i> , 1986, 25, 5678-5685.	1.2	13
61	Application of LC/MS/MS in the quantitation of SU101 and SU0020 uptake by 3T3/PDGFr cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2002, 28, 701-709.	1.4	13
62	Sequence analysis of the human thymidine kinase gene promoter: comparison with the human PCNA promoter. <i>DNA Sequence</i> , 1990, 1, 13-23.	0.7	11
63	Divalent cations regulate glucagon binding. Evidence for actions on receptor-Ns complexes and on receptors uncoupled from Ns. <i>Biochemistry</i> , 1988, 27, 1111-1116.	1.2	9
64	N-aryl cinnamides: A novel class of rigid and highly potent leukotriene B4 receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1997, 7, 949-954.	1.0	9
65	SU11657 Enhances Radiosensitivity of Human Meningioma Cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1213-1218.	0.4	9
66	Merged Screening for Human Immunodeficiency Virus Tat and Rev Inhibitors. <i>Journal of Biomolecular Screening</i> , 2001, 6, 179-187.	2.6	8
67	Regulation of the Expression of Cell Cycle Genes. <i>Annals of the New York Academy of Sciences</i> , 1988, 551, 283-289.	1.8	6
68	Inhibition of in vitro tumor cell proliferation by cytokines induced by combinations of TLR or TLR and TCR agonists. <i>International Immunopharmacology</i> , 2007, 7, 1471-1482.	1.7	5
69	CCAAT-box contributions to human thymidine kinase mRNA expression. <i>Journal of Cellular Biochemistry</i> , 1995, 57, 701-710.	1.2	4
70	Endothelin-I induces gene expression through stimulation of endothelin type a receptors in normal rat kidney cells. <i>Journal of Cellular Physiology</i> , 1995, 164, 491-498.	2.0	4
71	Immune response modifiers: Imiquimod and future drugs for modulating the immune response. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006, 3, 343-352.	0.5	4
72	Protein that binds to the distal, but not to the proximal, CCAAT of the human thymidine kinase gene promoter. <i>Journal of Cellular Biochemistry</i> , 1995, 57, 711-723.	1.2	2

#	ARTICLE	IF	CITATIONS
73	Enhancing radiation-induced inhibition of angiogenesis and tumor growth by an alpha-V-beta-3 integrin receptor antagonist. International Journal of Radiation Oncology Biology Physics, 2003, 57, S319-S320.	0.4	2
74	Receptor Tyrosine Kinases in Angiogenesis. , 2002, , 409-452.		2
75	Development of the First Generation c-Met Kinase Inhibitors: Beginning of a Path to a New Treatment for Cancer. Molecular Cancer Therapeutics, 2011, 10, 2022-2023.	1.9	0
76	Multimodal Therapies for Pancreatic Cancer. , 2014, , 39-73.		0
77	Inhibition Of Vascular Endothelial Growth Factor (Vegf) And Stem- Cell Factor (Scf) Receptor Kinases As Therapeutic Targets For The Treatment Of Human Diseases. , 2000, , .		0
78	GENE EXPRESSION AT THE G1/S BOUNDARY. , 1990, , 139-153.		0
79	Receptor Tyrosine Kinases in Angiogenesis. , 0, , 409-452.		0